Dianthus Therapeutics, Inc. (DNTH)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Marino Garcia M.B.A. | President, CEO & Director | 943.8k | -- | 1966 |
| Mr. Ryan Savitz | Chief Financial Officer & Chief Business Officer | 655.48k | -- | 1989 |
| Mr. Simrat Randhawa M.B.A., M.D. | Chief Medical Officer | 688.6k | -- | 1970 |
| Mr. Edward G. Carr | Chief Accounting Officer | -- | -- | 1969 |
| Mr. Judson Taylor | Senior VP & Head of Technical Operations | -- | -- | -- |
| Ms. Jennifer Davis Ruff | VP and Head of Investor Relations & Corporate Affairs. | -- | -- | -- |
| Mr. Adam M. Veness Esq. | Senior VP, General Counsel & Secretary | -- | -- | 1986 |
| Ms. Kristina Maximenko | Chief People Officer | -- | -- | -- |
| Ms. Rashieda Gluck | Head of Clinical Development Operations | -- | -- | -- |
| Mr. Scott Nogi M.B.A. | Head of Business Operations | -- | -- | -- |
Dianthus Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 78
Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
August 6, 2025 at 8:00 PM UTC - August 11, 2025 at 8:00 PM UTC
Dianthus Therapeutics, Inc. Earnings Date
Recent Events
October 7, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission